Article Text

other Versions

PDF
Research paper
MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS
  1. Mike P Wattjes1,2,
  2. Martijn T Wijburg1,2,3,
  3. Anke Vennegoor1,3,
  4. Birgit I Witte4,
  5. Marlieke de Vos1,2,
  6. Nancy D Richert5,
  7. Bernard M J Uitdehaag1,3,
  8. Frederik Barkhof1,2,
  9. Joep Killestein1,3
  10. on behalf of the Dutch-Belgian Natalizumab-associated PML study group
    1. 1MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    2. 2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands
    3. 3Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    4. 4Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands
    5. 5Multiple Sclerosis Clinical Development Group, Biogen, Cambridge, Massachusetts, USA
    1. Correspondence to Dr Mike P Wattjes, Department of Radiology and Nuclear Medicine, MS Center Amsterdam, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands; m.wattjes{at}vumc.nl

    Abstract

    Objective The early detection of MRI findings suggestive of immune reconstitution inflammatory syndrome (IRIS) in natalizumab-associated progressive multifocal leukoencephalopathy (PML) is of crucial clinical relevance in terms of treatment decision-making and clinical outcome. The aim of this study was to investigate the earliest imaging characteristics of PML-IRIS manifestation in natalizumab-treated patients with multiple sclerosis and describe an imaging pattern that might aid in the early and specific diagnosis.

    Methods This was a retrospective study assessing brain MRI of 26 patients with natalizumab-associated PML presenting with lesions suggestive of PML-IRIS during follow-up. MRI findings were evaluated considering the imaging findings such as mass effect, swelling, contrast enhancement, new perivascular T2 lesions and signs suggestive of meningeal inflammation.

    Results Contrast enhancement was the most common imaging sign suggestive of PML-IRIS, seen in 92.3% of the patients (with patchy and/or punctuate pattern in 70.8% and 45.8% respectively), followed by new T2 lesions with a perivascular distribution pattern (34.6%). In those patients with contrast enhancement, the enhancement was present in the lesion periphery in 95.8% of the patients. Contrast-enhancing lesions with a perivascular distribution pattern outside of the PML lesion were observed in 33.3% of the patients. The most common overall pattern was contrast enhancement in the border of the PML lesion with either a patchy or punctuate appearance in 88.5% of all patients.

    Conclusions Contrast enhancement is the most common earliest sign of natalizumab-associated PML-IRIS with a frequent imaging pattern of contrast-enhancing lesions with either a patchy or punctuate appearance in the border of the PML lesion.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.